Ironwood Pharmaceuticals
IRWD
3.70
-0.05
-1.33%
Ironwood Pharmaceuticals
US · IRWD
#3609 by market cap
3.70
-0.05
-1.33%
Live - 5344 symbols - heartbeat 484s ago
· 2026-10-08 10:11
Pre-market
3.71
-1.07%
After-hours
3.54
-5.59%
Overnight
3.72
-0.80%
- Market cap
- 611.39M
- P/E (TTM)i
- 4.68
- P/Bi
- -3.78
- EPSi
- 0.15
- Div yieldi
- 0.00%
- 52W posi
- 52%
Reader sentiment
Are you bullish or bearish on IRWD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.52, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -15.72% YoY
Margins
- Operating margin
- 40.10%
- Net margin
- 8.11%
Key ratios & quality
- Enterprise valuei
- 983.86M
- Altman Z-Scorei
- -3.52
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 346.64M | 428.41M | 389.52M | 413.75M | 410.60M | 442.74M | 351.41M | 296.15M |
| Gross profit | 313.89M | 404.54M | 386.39M | -- | -- | -- | -- | -- |
| Selling & admin expenses | 219.68M | 172.45M | 140.00M | 111.13M | 115.99M | 158.31M | 144.27M | 82.26M |
| Research & development | 101.06M | 115.04M | 88.06M | 70.41M | 44.27M | 116.09M | 111.42M | 95.14M |
| Operating profit | -14.96M | 117.04M | 158.32M | 232.22M | 250.34M | 168.34M | 95.72M | 118.76M |
| Pretax profit | -194.15M | 58.94M | 108.86M | 200.66M | 252.42M | -948.07M | 65.20M | 70.03M |
| Tax | 0 | 0 | 2.69M | -327.79M | 77.36M | 83.49M | 64.32M | 46.01M |
| Net profit | -282.37M | 21.51M | 106.18M | 528.45M | 175.07M | -1.03B | 880.00K | 24.02M |
| Basic EPS | -2 | 0 | 1 | 3 | 1 | -6 | 0 | 0 |
| Diluted EPS | -1.85 | 0.14 | 0.66 | 3.21 | 0.96 | -6.45 | 0.01 | 0.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 41.14M | 85.24M | 122.06M | 47.71M | 106.51M | 113.04M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 24.26M | 16.80M | 21.91M | 19.29M | 12.03M | 11.31M |
| Research & development | 27.43M | 23.37M | 22.47M | 21.86M | 21.94M | 22.42M |
| Operating profit | -10.55M | 45.07M | 77.68M | 6.55M | 72.53M | 79.31M |
| Pretax profit | -36.27M | 37.82M | 68.02M | 455.00K | 65.17M | 73.73M |
| Tax | 1.11M | 14.22M | 27.94M | 2.73M | 24.40M | 22.44M |
| Net profit | -37.39M | 23.60M | 40.08M | -2.28M | 40.77M | 51.29M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.23 | 0.14 | 0.23 | -0.01 | 0.24 | 0.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 266.44M | 306.85M | 495.84M | 745.23M | 780.63M | 233.29M | 182.37M | 274.18M |
| Cash & ST investments | 173.17M | 177.02M | 362.56M | 620.13M | 656.20M | 92.15M | 88.56M | 215.46M |
| Inventory | 0 | 648.00K | -- | -- | -- | -- | -- | -- |
| Total assets | 332.05M | 402.75M | 559.24M | 1.13B | 1.10B | 471.07M | 350.91M | 396.90M |
| Total current liabilities | 119.52M | 40.93M | 32.17M | 161.70M | 25.53M | 276.10M | 38.85M | 242.22M |
| Short-term debt | 47.63M | 1.15M | 3.13M | 119.99M | 3.07M | 202.69M | 3.19M | 202.93M |
| Long-term debt | 366.14M | 407.99M | 430.26M | 337.33M | 396.25M | 498.31M | 583.99M | 385.00M |
| Total liabilities | 528,421,000.00 | 495,999,000.00 | 496,598,000.00 | 521,016,000.00 | 448,141,000.00 | 817,368,000.00 | 652,243,000.00 | 658,736,000.00 |
| Total equity | -196.37M | -93.25M | 62.64M | 605.91M | 652.38M | -346.30M | -301.34M | -261.84M |
| Retained earnings | -1.59B | -1.57B | -1.47B | -937.61M | -696.38M | -1.70B | -1.70B | -1.67B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 160.58M | 191.75M | 273.84M | 274.18M | 332.29M | 199.20M |
| Cash & ST investments | 108.48M | 92.85M | 140.41M | 215.46M | 220.47M | 79.13M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 327.21M | 342.95M | 396.06M | 396.90M | 434.57M | 285.13M |
| Total current liabilities | 48.10M | 232.53M | 242.50M | 242.22M | 236.31M | 32.85M |
| Short-term debt | 3.20M | 202.55M | 202.74M | 202.93M | 203.12M | 3.29M |
| Long-term debt | 584.16M | 385.00M | 385.00M | 385.00M | 385.00M | 385.00M |
| Total liabilities | 661,266,000.00 | 651,108,000.00 | 660,219,000.00 | 658,736,000.00 | 651,710,000.00 | 446,971,000.00 |
| Total equity | -334.05M | -308.16M | -264.16M | -261.84M | -217.14M | -161.84M |
| Retained earnings | -1.74B | -1.71B | -1.67B | -1.67B | -1.63B | -1.58B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -70.88M | 10.73M | 168.84M | 261.90M | 273.76M | 183.43M | 103.55M | 127.04M |
| Depreciation & amortization | 11.97M | 5.58M | 3.56M | 1.50M | 1.42M | 1.58M | 2.01M | 1.88M |
| Free cash flow | -71.23M | 3.54M | 166.99M | 261.63M | 273.63M | 183.15M | 103.41M | 127.01M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 0 | -24.13M | -126.39M | 0 | -- | -- |
| Ending cash balance | 180.85M | 179.24M | 364.78M | 621.86M | 657.94M | 92.15M | 88.56M | 215.46M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 19.95M | -15.07M | 47.58M | 74.58M | 5.12M | 58.28M |
| Depreciation & amortization | 479.00K | 467.00K | 475.00K | 460.00K | 443.00K | 457.00K |
| Free cash flow | 19.92M | -15.07M | 47.58M | 74.58M | 5.12M | 58.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 108.48M | 92.85M | 140.41M | 215.46M | 220.47M | 79.13M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | 158.09 | 27.83 | -654.88 | -- | -- |
| ROA %i | -60.22 | 5.85 | 22.07 | 62.68 | 15.72 | -127.54 | 0.21 | 6.42 |
| ROIC %i | -- | -- | -- | 68.92 | 16.16 | -139.15 | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -70.58 | 22.30 | 35.52 | 56.03 | 63.33 | -209.25 | 27.95 | 34.70 |
| FCF / sales %i | -- | 0.83 | 42.87 | 63.23 | 66.64 | 41.37 | 29.43 | 42.89 |
| Current ratioi | 2.23 | 7.50 | 15.41 | 4.61 | 30.58 | 0.84 | 4.69 | 1.13 |
| Quick ratioi | 2.13 | 7.19 | 15.07 | 4.54 | 30.23 | 0.80 | 4.39 | 1.08 |
| Debt / assetsi | 124.66 | 107.07 | 81.13 | 42.22 | 37.79 | 151.90 | 170.84 | 150.62 |
| LT debt / equityi | -- | -- | 719.31 | 58.72 | 63.28 | -- | -- | -- |
| Interest coveragei | -6.49 | 2.61 | 4.69 | 7.44 | 34.22 | -42.83 | 2.97 | 3.14 |
| Revenue CAGR (3Y) %i | 32.34 | 16.07 | 9.30 | 6.08 | -1.41 | 4.36 | -5.30 | -10.32 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | 101.17 | -- | -88.15 | -48.42 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | 326.14 | 3.13 | -26.61 | -22.57 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -8.44 | -2.14 | 7.27 | 6.42 | 26.83 | 41.35 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.28 | 25.18 | 37.56 | 34.70 | 56.78 | 61.66 |
| FCF / sales %i | 24.68 | 9.70 | 19.96 | 42.89 | 31.04 | 47.66 |
| Current ratioi | 3.34 | 0.82 | 1.13 | 1.13 | 1.41 | 6.06 |
| Quick ratioi | 3.08 | 0.77 | 1.08 | 1.08 | 1.38 | 5.84 |
| Debt / assetsi | 183.09 | 174.57 | 151.05 | 150.62 | 137.46 | 139.19 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 1.70 | 2.23 | 3.77 | 3.14 | 6.07 | 7.35 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Human therapeutics100.00%
Quote time 2026-10-08 10:11:29 · For reference only, not investment advice and not tailored to your situation.